Completed × NIH × Sarcoma × Clear all
NCT03213665 2025-01-27

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 12 charts
NCT03213678 2025-01-27

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 12 charts
NCT03220035 2025-01-27

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
4 enrolled 12 charts
NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled 12 charts
NCT03526250 2024-11-01

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 11 charts
NCT00020267 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT01154452 2018-08-15

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
78 enrolled 11 charts
NCT01170299 2016-11-01

Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer

National Cancer Institute (NCI)

Phase NA Completed
177 enrolled
NCT00720174 2016-05-17

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00020150 2015-04-29

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
NCT00562380 2013-07-18

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
64 enrolled